Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Daratumumab, bortezomib and dexamethasone at first relapse for patients with multiple myeloma: A real-world multicentre UK retrospective analysis.
McMillan A, Basu S, Karunanithi K, Parkins E, Lau EYM, Cook G, Parrish C, Al-Kaisi F, Pratt G, Shafeek S, Jenkins S, Memon D, Bygrave C, Papanikolaou X, Maisel T, Hassan S, Moosai S, Chander G, Rakesh P, Kishore B, Karim F, Talbot G, Wandroo F, Yong K, Popat R. McMillan A, et al. Among authors: bygrave c. Br J Haematol. 2023 May;201(4):682-689. doi: 10.1111/bjh.18703. Epub 2023 Feb 23. Br J Haematol. 2023. PMID: 36822820
Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy.
Cook G, John Ashcroft A, Pratt G, Popat R, Ramasamy K, Kaiser M, Jenner M, Henshaw S, Hall R, Sive J, Stern S, Streetly M, Bygrave C, Soutar R, Rabin N, Jackson GH; United Kingdom Myeloma Forum. Cook G, et al. Among authors: bygrave c. Br J Haematol. 2020 Jul;190(2):e83-e86. doi: 10.1111/bjh.16874. Epub 2020 Jun 10. Br J Haematol. 2020. PMID: 32438482 Free PMC article. No abstract available.
Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma.
Bygrave C, Pawlyn C, Davies F, Craig Z, Cairns D, Hockaday A, Jenner M, Cook G, Drayson M, Owen R, Gregory W, Morgan G, Jackson G, Kaiser M. Bygrave C, et al. Br J Haematol. 2021 May;193(3):551-555. doi: 10.1111/bjh.16793. Epub 2020 Jun 10. Br J Haematol. 2021. PMID: 32524584 Free PMC article. Clinical Trial.
COVID-19 and myeloma clinical research - experience from the CARDAMON clinical trial.
Camilleri M, Sive J, Wilson W, Pang G, Jenner R, Phillips E, Popat R, Ramasamy K, Bygrave C, Dadaga T, Streetly M, Cavenagh J, Chapman M, Barrington S, Pike L, Owen R, Clifton-Hadley L, Yong K. Camilleri M, et al. Among authors: bygrave c. Br J Haematol. 2021 Jan;192(1):e14-e16. doi: 10.1111/bjh.17168. Epub 2020 Nov 21. Br J Haematol. 2021. PMID: 33222153 Free PMC article. Clinical Trial. No abstract available.
Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (≥2nd relapse) refractory myeloma: a multicenter real world UK experience.
Maouche N, Kishore B, Jenner MW, Boyd K, Bhatti Z, Bird SA, Chander G, Robinson R, Vallance GD, Offer M, Kothari J, Peniket A, Aitchison R, Dungarwalla M, Collings F, Bygrave C, Ramasamy K. Maouche N, et al. Among authors: bygrave c. Leuk Lymphoma. 2021 Jun;62(6):1396-1404. doi: 10.1080/10428194.2020.1864355. Epub 2020 Dec 25. Leuk Lymphoma. 2021. PMID: 33356703
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
Camilleri M, Cuadrado M, Phillips E, Wilson W, Jenner R, Pang G, Kamora S, Streetly M, Popat R, Bygrave C, Owen R, Cavenagh J, Chapman M, Sive J, Eccersley L, Sheaff M, Benjamin R, Ramasamy K, Cook G, Virchis A, Chavda SJ, Clifton-Hadley L, Scully MA, Yong K. Camilleri M, et al. Among authors: bygrave c. Br J Haematol. 2021 May;193(4):750-760. doi: 10.1111/bjh.17377. Epub 2021 Mar 1. Br J Haematol. 2021. PMID: 33650100 Free PMC article. Clinical Trial.
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive).
Yong KL, Hinsley S, Auner HW, Bygrave C, Kaiser MF, Ramasamy K, De Tute RM, Sherratt D, Flanagan L, Garg M, Hawkins S, Williams C, Cavenagh J, Rabin NK, Croft J, Morgan G, Davies F, Owen RG, Brown SR. Yong KL, et al. Among authors: bygrave c. Haematologica. 2021 Oct 1;106(10):2694-2706. doi: 10.3324/haematol.2021.278399. Haematologica. 2021. PMID: 33910333 Free PMC article. Clinical Trial.
Efficacy of Isatuximab With Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of a UK-Wide Real-World Dataset.
Djebbari F, Rampotas A, Vallance G, Panitsas F, Basker N, Sangha G, Salhan B, Karim F, Al-Kaisi F, Gudger A, Ngu L, Poynton M, Lam HPJ, Morgan L, Yang L, Young J, Walker M, Tsagkaraki I, Anderson L, Chauhan SR, Maddams R, Soutar R, Triantafillou M, Prideaux S, Obeidalla A, Bygrave C, Basu S, Ramasamy K. Djebbari F, et al. Among authors: bygrave c. Hemasphere. 2022 May 26;6(6):e738. doi: 10.1097/HS9.0000000000000738. eCollection 2022 Jun. Hemasphere. 2022. PMID: 35651713 Free PMC article.
Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study.
Djebbari F, Rampotas A, Vallance G, Panitsas F, Basker N, Sangha G, Salhan B, Karim F, Firas AK, Gudger A, Ngu L, Poynton M, Lam HPJ, Morgan L, Yang L, Young J, Walker M, Tsagkaraki I, Anderson L, Chauhan SR, Maddams R, Soutar R, Triantafillou M, Prideaux S, Obeidalla A, Eyre TA, Bygrave C, Basu S, Ramasamy K. Djebbari F, et al. Among authors: bygrave c. Hematology. 2022 Dec;27(1):691-699. doi: 10.1080/16078454.2022.2082725. Hematology. 2022. PMID: 35666686 Free article.
28 results